Integra LifeSciences Holdings Corporation P/E Ratio 2008–2025
Integra LifeSciences Holdings Corporation reported 51.85 of price-to-earnings ratio for fiscal 2023. That was 99.7% higher than fiscal 2022. Compared with fiscal 2018, the change was -17.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | — | — |
| FY 2023 | 51.85 | +99.7% |
| FY 2022 | 25.96 | -23.3% |
| FY 2021 | 33.83 | -18.2% |
| FY 2020 | 41.35 | -58.8% |
| FY 2019 | 100.48 | +60.4% |
| FY 2018 | 62.64 | +7.3% |
| FY 2017 | 58.37 | +27.9% |
| FY 2016 | 45.63 | — |
| FY 2015 | — | — |
| FY 2014 | 188.59 | — |
| FY 2013 | — | — |
| FY 2012 | 48.94 | +66.8% |
| FY 2011 | 29.34 | -25.6% |
| FY 2010 | 39.42 | +2.9% |
| FY 2009 | 38.32 | +14.4% |
| FY 2008 | 33.50 | — |
Source: Integra LifeSciences Holdings Corporation SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open IART 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Integra LifeSciences Holdings Corporation reported 51.85 of price-to-earnings ratio for fiscal 2023. That was 99.7% higher than fiscal 2022. Compared with fiscal 2018, the change was -17.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Integra LifeSciences Holdings Corporation
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeIntegra LifeSciences Holdings Corporation — frequently asked questions
What is Integra LifeSciences Holdings Corporation's price-to-earnings ratio?
Integra LifeSciences Holdings Corporation (IART) reported price-to-earnings ratio of 51.85 for fiscal year 2023, per its SEC filings.
How has Integra LifeSciences Holdings Corporation's price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, IART's price-to-earnings ratio grew at roughly 2.6% per year (compound annual rate), from 33.50 to 51.85.
Where does this data come from?
Figures are computed from Integra LifeSciences Holdings Corporation's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More IART financial history
Full IART fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →